The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - University of Southern California
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Katherine Kim
No Relationships to Disclose
 
Shiva Sreenath Andrali
No Relationships to Disclose
 
Marie Del Rosario
No Relationships to Disclose
 
William W. Tseng
No Relationships to Disclose
 
Seth Pollack
Consulting or Advisory Role - Amgen; Lilly; Nektar; Omeros
Research Funding - EMD Serono (Inst); Epizyme (Inst); Immune Design (Inst); Janssen Oncology; Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Merck (Inst); OncoSec; Presage Biosciences (Inst)
Travel, Accommodations, Expenses - Lilly/ImClone
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma